Gland Pharma Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Srinivas Sadu

Chief executive officer

₹70.2m

Total compensation

CEO salary percentage95.3%
CEO tenure5.8yrs
CEO ownershipn/a
Management average tenureless than a year
Board average tenure4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Srinivas Sadu's remuneration changed compared to Gland Pharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹7b

Jun 30 2024n/an/a

₹7b

Mar 31 2024₹70m₹67m

₹8b

Dec 31 2023n/an/a

₹7b

Sep 30 2023n/an/a

₹7b

Jun 30 2023n/an/a

₹7b

Mar 31 2023₹124m₹61m

₹8b

Dec 31 2022n/an/a

₹10b

Sep 30 2022n/an/a

₹10b

Jun 30 2022n/an/a

₹11b

Mar 31 2022₹124m₹61m

₹12b

Dec 31 2021n/an/a

₹12b

Sep 30 2021n/an/a

₹11b

Jun 30 2021n/an/a

₹10b

Mar 31 2021₹89m₹31m

₹10b

Dec 31 2020n/an/a

₹9b

Jun 30 2020n/an/a

₹9b

Mar 31 2020₹59m₹32m

₹8b

Mar 31 2019₹23mn/a

₹5b

Mar 31 2018₹11m₹5m

₹3b

Compensation vs Market: Srinivas's total compensation ($USD818.79K) is above average for companies of similar size in the Indian market ($USD578.34K).

Compensation vs Earnings: Srinivas's compensation has been consistent with company performance over the past year.


CEO

Srinivas Sadu (55 yo)

5.8yrs

Tenure

₹70,150,000

Compensation

Mr. Srinivas Sadu, B. Pharm, M. S., MBA has been Executive Director and Chief Executive Officer at Gland Pharma Ltd. since April 25, 2019 and serves as its Executive Chairman from June 10, 2024. He had bee...


Leadership Team

NamePositionTenureCompensationOwnership
Srinivas Sadu
CEO & Executive Chairman5.8yrs₹70.15mno data
Ravi Mitra
Chief Financial Officer5.3yrs₹20.45mno data
Sampath Pallerlamudi
Company Secretary & Vice-President of Compliance & CSRno data₹6.05mno data
Satnam Loomba
Chief Operating Officerless than a yearno datano data
Ankit Gupta
Head of Investments1.3yrsno datano data
Surinder Koul
Head of Domestic Marketingless than a yearno datano data
K Rao
Head of Qualityless than a yearno data0.0012%
₹ 3.9m
R.V.R. Sastry
Senior Vice President of R&Dless than a yearno datano data
Rong Wu
Chief Financial Controllerno datano data0.000020%
₹ 62.3k

0.8yrs

Average Tenure

51yo

Average Age

Experienced Management: 543245's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Srinivas Sadu
CEO & Executive Chairman5.8yrs₹70.15mno data
Naina Lal Kidwai
Independent Director3.7yrs₹10.50mno data
Udo Vetter
Independent Director6.9yrs₹3.00mno data
Essaji Vahanvati
Independent Director4.3yrs₹3.00mno data
Wenjie Zhang
Non-Executive and Non-Independent Directorless than a yearno datano data
Jia Ai Zhang
Non-Independent Non Executive Director3.7yrsno datano data
Satyanarayana Chavali
Independent Director6.2yrs₹3.00mno data
Wei Huang
Non-Executive Non-Independent Directorless than a yearno datano data

4.0yrs

Average Tenure

60yo

Average Age

Experienced Board: 543245's board of directors are considered experienced (4 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/06 03:18
End of Day Share Price 2025/01/06 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gland Pharma Limited is covered by 21 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Prashant NairAmbit Capital
Neha ManpuriaBofA Global Research
Vivek AgrawalCitigroup Inc